Zouboulis, C. C.; Okun, M. M.; Gniadecki, R.; Foley, P. A.; Lynde, C.; Weisman, J.; Karunaratne, P.; Williams, D. A. Adalimumab Efficacy in Hidradenitis Suppurativa Patients Is Sustained at Least Three Years With Weekly Dosing: Results from a Phase 3 Open-Label Extension Study (PIONEER). J of Skin 2017, 1, s128.